On Friday, Opexa Therapeutics Inc (NASDAQ:OPXA)’s shares declined -6.51% to $0.560.
Opexa Therapeutics Inc (OPXA) declared that Neil K. Warma, President and Chief Executive Officer, will present at the Biotechnology Industry Organization (BIO) 2015 International Convention on Tuesday, June 16, 2015, at 1:45 p.m. EDT in Theater 1. The conference will be held at The Pennsylvania Convention Center (June 15-18, 2015, Philadelphia, PA).
Opexa Therapeutics, Inc., a biopharmaceutical company, develops personalized immunotherapy to treat multiple sclerosis (MS) and other autoimmune diseases, such as neuromyelitis optica (NMO) based on its proprietary T-cell technology.
Gran Tierra Energy Inc. (NYSEMKT:GTE)’s shares gained 0.66% to $3.06.
Gran Tierra Energy Inc. (GTE) is making Colombian oil deals the focus of its expansion this year as the company steers investment plans away from Peru and Brazil, Chief Executive Officer Gary Guidry said.
The Calgary-based explorer of South American oil anticipates to close deals in the Andean nation before year-end to enhance output and reserves, said Guidry, who took over as CEO earlier this month. He’s considering potential joint ventures, takeovers and asset purchases.
Guidry was named president and CEO of Gran Tierra on May 8 as part of a shake-up led by Toronto-based hedge fund West Face Capital Inc., which owns about 9.8 percent of the company. Guidry’s drilling plan for Colombia will be declared in June, when shareholders hold a general meeting.
West Face, run by Greg Boland, blamed a decline in Gran Tierra’s value since the starting of 2011 on “failed high-risk, high-cost” exploration in Peru, Argentina and Brazil.
The oil producer may sell or seek joint ventures for assets in Peru and Brazil to ensure capital is focused on Colombia, Guidry said.
The company produced a daily average of 24,015 barrels of oil equivalent in the first quarter of 2015, mainly light oil from the Putumayo basin in southern Colombia.
Gran Tierra Energy Inc., an independent energy company, engages in the acquisition, exploration, development, and production of oil and gas properties in Colombia, Peru, and Brazil. As of December 31, 2014, the company’s acreage comprised 3.4 million gross acres covering 16 exploration and production contracts in Colombia; 47,734 gross acres covering 7 exploration blocks in Brazil; and 5.7 million gross acres covering 5 exploration licenses in Peru.
At the end of Friday’s trade, Baker Hughes Incorporated (NYSE:BHI)‘s shares dipped -0.42% to $64.13.
Baker Hughes Incorporated (BHI) declared that the international rig count for May 2015 was 1,158, down 44 from the 1,202 counted in April 2015, and down 192 from the 1,350 counted in May 2014. The international offshore rig count for May 2015 was 284, down 16 from the 300 counted in April 2015, and down 42 from the 326 counted in May 2014.
The average U.S. rig count for May 2015 was 889, down 87 from the 976 counted in April 2015, and down 970 from the 1,859 counted in May 2014. The average Canadian rig count for May 2015 was 80, down 10 from the 90 counted in April 2015, and down 82 from the 162 counted in May 2014.
Baker Hughes Incorporated supplies oilfield services, products, technology, and systems to the oil and natural gas industry worldwide. The company offers drilling and evaluation products and services, which comprise drill bits for performance drilling, hole enlargement, and coring; conventional and rotary steerable systems used to drill wells; measurement-while-drilling and logging-while-drilling systems to perform reservoir navigation services; drilling optimization services; tools for coil tubing drilling and wellbore re-entry systems; coring drilling systems; surface logging; emulsion and water-based drilling fluids systems; reservoir drill-in fluids; and fluids environmental services.
Oragenics Inc (NYSEMKT:OGEN), ended its Friday’s trading session with 43.45% gain, and closed at $2.08.
Intrexon Corp (XON) and Oragenics (OGEN), declared a new Exclusive Channel Collaboration (ECC) to pursue development of biotherapeutics for oral mucositis (OM) and other diseases and conditions of the oral cavity, throat, and esophagus, isncluding clinical advancement of the ActoBiotic™ AG013 for the treatment of OM. OM results in the painful inflammation and ulceration of the membranes lining the oral cavity, throat, and esophagus and is among the most frequently reported adverse events associated with cancer therapy affecting up to 500,000 patients annually. At present there is no drug approved to prevent the condition broadly and therapies are primarily palliative, alleviating symptoms without addressing the underlying pathology, resulting in a significant unmet medical need.
Intrexon Corporation, a biotechnology company, operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that comprise of key genetic components.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
